Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy

Study summary

This study collects information on the side effects of proton therapy and detailed information on the proton therapy treatment plan itself. This may help researchers develop methods to predict the risk of side effects for future patients and learn the long-term benefit of proton therapy.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedQuality-of-Life Assessment and Questionnaire Administration

The study team can explain what participation involves.

Who it may be forBreast Carcinoma · Esophageal Carcinoma

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 12, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?M.D. Anderson Cancer Center

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: M.D. Anderson Cancer Center
Interventions being studied: Other: Quality-of-Life Assessment; Other: Questionnaire Administration

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Radiation therapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

All patients scheduled for radiation treatment with protons at UTMDACC are eligible for this protocol
Patients must sign a study-specific consent form prior to study entry

Reasons someone may not be able to joinExclusion criteria

Patients who are unable or unwilling to attend the required periodic follow-ups either at M.D. Anderson or at a different site

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

M D Anderson Cancer CenterHouston, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 12, 2026. Always confirm current availability with the study team.

View original record ↗